Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert V Higgins

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer|May 21, 2011
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancerLaura J Havrilesky, Robin Pokrzywinski, Dennis Revicki, et al.
Gynecologic Oncology|October 13, 2018
Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancerR Wendel Naumann, Jacob C Morris, David L Tait, et al.
Journal of Molecular Biology|March 1, 2006
Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesisJean-Luc C Mougeot, Zahra Bahrani-Mostafavi, Judy C Vachris, et al.
Gynecologic Oncology|April 26, 2003
Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigationJames L Wilder, Edward Pavlik, John M Straughn, et al.
Gynecologic Oncology|July 22, 2017
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group studyJohn K Chan, Wei Deng, Robert V Higgins, et al.
Cancer|November 11, 2011
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancerAngeles Alvarez Secord, Andrew Berchuck, Robert V Higgins, et al.
Gynecologic Oncology|September 28, 2011
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trialRobin Pokrzywinski, Angeles Alvarez Secord, Laura J Havrilesky, et al.
Gynecologic Oncology|August 8, 2024
Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomesJennifer Vaz, Rachael Piver, Bogna Brzezinska, et al.
Gynecologic Oncology|December 7, 2002
Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapyJeanne M Schilder, Amy M Thompson, Paul D DePriest, et al.
Gynecologic Oncology|January 17, 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, Jan H Beumer, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer|May 21, 2011
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancerLaura J Havrilesky, Robin Pokrzywinski, Dennis Revicki, et al.
Gynecologic Oncology|October 13, 2018
Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancerR Wendel Naumann, Jacob C Morris, David L Tait, et al.
Journal of Molecular Biology|March 1, 2006
Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesisJean-Luc C Mougeot, Zahra Bahrani-Mostafavi, Judy C Vachris, et al.
Gynecologic Oncology|April 26, 2003
Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigationJames L Wilder, Edward Pavlik, John M Straughn, et al.
Gynecologic Oncology|July 22, 2017
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group studyJohn K Chan, Wei Deng, Robert V Higgins, et al.
Cancer|November 11, 2011
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancerAngeles Alvarez Secord, Andrew Berchuck, Robert V Higgins, et al.
Gynecologic Oncology|September 28, 2011
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trialRobin Pokrzywinski, Angeles Alvarez Secord, Laura J Havrilesky, et al.
Gynecologic Oncology|August 8, 2024
Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomesJennifer Vaz, Rachael Piver, Bogna Brzezinska, et al.
Gynecologic Oncology|December 7, 2002
Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapyJeanne M Schilder, Amy M Thompson, Paul D DePriest, et al.
Gynecologic Oncology|January 17, 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, Jan H Beumer, et al.
Pageof 2